Skip to content

Study · Randomized controlled trial · n = 125 · 2005

11 results

[Clinical trial on the effectiveness and safety of triptorelin in treatment of uterine leiomyoma].

Zhou YF, Yang DZ, Hu LN, Zheng SR

Zhonghua fu chan ke za zhi1 Jul 2005

PMID16080872 (opens in a new tab)PepBankPUB-16080872
Publisher pageAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyoma, uterine volume fell with triptorelin, with no significant difference from leuprorelin.

    In plain wordsIn women with uterine leiomyoma, triptorelin reduced uterine volume similarly to leuprorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeUterine volume reduction
    Study

    n = 125

    Comparator
    Leuprorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Median uterine volume decrease
    51%
    triptorelin
    Median uterine volume decrease
    49%
    leuprorelin

    Source sentences

    Summary
    The uterine volumes were similar before treatment between the triptorelin group and the leuprorelin group and were decreased significantly after drug therapy (P 0.05).
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyoma, largest leiomyoma volume fell with triptorelin, with no significant difference from leuprorelin.

    In plain wordsIn women with uterine leiomyoma, triptorelin reduced the largest leiomyoma volume similarly to leuprorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeLargest leiomyoma volume reduction
    Study

    n = 125

    Comparator
    Leuprorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Median leiomyoma volume decrease
    50%
    triptorelin
    Median leiomyoma volume decrease
    48%
    leuprorelin

    Source sentences

    Summary
    The volumes of the largest leiomyoma decreased significantly after drug therapy (P 0.05).
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyoma, 94% had estradiol below 183 pmol/L in both triptorelin and leuprorelin groups.

    In plain wordsIn women with uterine leiomyoma, 94% had low estradiol in both triptorelin and leuprorelin groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableEstradiol below threshold
    Study

    n = 125

    Comparator
    Leuprorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Estradiol below 183 pmol/L
    94%
    triptorelin
    Estradiol below 183 pmol/L
    94%
    leuprorelin

    Source sentences

    Summary
    Patients with serum level of 17beta-estradiol < 183 pmol/L accounted for 94% in both groups.
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyoma, hemoglobin increased significantly after treatment in both triptorelin and leuprorelin groups.

    In plain wordsIn women with uterine leiomyoma, hemoglobin increased from baseline in both triptorelin and leuprorelin groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseHemoglobin
    Study

    n = 125

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The hemoglobin and serum ferrum levels were both significantly increased in the two groups after treatment (P < 0.05).
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyoma, serum ferrum increased significantly after treatment in both triptorelin and leuprorelin groups.

    In plain wordsIn women with uterine leiomyoma, blood iron increased from baseline in both triptorelin and leuprorelin groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseSerum ferrum
    Study

    n = 125

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The hemoglobin and serum ferrum levels were both significantly increased in the two groups after treatment (P < 0.05).
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyoma, amenorrhea rates did not differ significantly between triptorelin and leuprorelin.

    In plain wordsIn women with uterine leiomyoma, triptorelin and leuprorelin produced similar rates of absent menstruation.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeAmenorrhea
    Study

    n = 125

    Comparator
    Leuprorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Amenorrhea
    97%
    triptorelin after 3 months
    Amenorrhea
    95%
    leuprorelin after 3 months

    Source sentences

    Summary
    The amenorrhea rates after 3 months of treatment were 97% in the triptorelin group and 95% in the leuprorelin group (P > 0.05).
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyoma, dysmenorrhea, noncyclic pelvic pain and pressure symptoms improved in both triptorelin and leuprorelin groups.

    In plain wordsIn women with uterine leiomyoma, menstrual pain, pelvic pain and pressure improved from baseline in both drug groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePelvic symptom relief
    Study

    n = 125

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Dysmenorrhea, noncyclic pelvic pain and pressure-like symptoms were relieved quickly and remarkably in both groups after treatment.
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  8. 08HumanRandomized controlled trialSafety outcome

    In women with uterine leiomyoma, adverse events occurred in 71% of patients in both triptorelin and leuprorelin groups.

    In plain wordsIn women with uterine leiomyoma, 71% reported adverse events in both triptorelin and leuprorelin groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableAdverse event rate
    Study

    n = 125

    Comparator
    Leuprorelin
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Adverse events
    71%
    triptorelin
    Adverse events
    71%
    leuprorelin

    Source sentences

    Summary
    The rates of adverse event occurred in 71% of patients in both groups.
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.
  9. 09HumanRandomized controlled trialSafety outcome

    In women with uterine leiomyoma, nine triptorelin patients and six leuprorelin patients required tibolone for marked climacteric-like symptoms.

    In plain wordsIn women with uterine leiomyoma, nine triptorelin patients versus six leuprorelin patients needed tibolone for marked menopause-like symptoms.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableClimacteric-like symptoms requiring add-back therapy
    Study

    n = 125

    Comparator
    Leuprorelin
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Add-back therapy with tibolone
    9 patients
    triptorelin
    Add-back therapy with tibolone
    6 patients
    leuprorelin

    Source sentences

    Summary
    Nine patients in the triptorelin group and 6 in the leuprorelin group received add-back therapy with tibolone 1.25-2.50 mg/d because of remarkable climacteric-like symptoms.
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In women with uterine leiomyoma treated with triptorelin or leuprorelin, main side effects included flare-up effects.

    In plain wordsIn women receiving triptorelin or leuprorelin for uterine leiomyoma, reported side effects included initial flare effects.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableFlare-up effects
    Study

    n = 125

    Outcome group
    Adverse events · Reproductive and sexual health

    Source sentences

    Summary
    The main side effects included flare-up effects and hypoestrogenic symptoms.
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In women with uterine leiomyoma treated with triptorelin or leuprorelin, main side effects included hypoestrogenic symptoms.

    In plain wordsIn women receiving triptorelin or leuprorelin for uterine leiomyoma, reported side effects included symptoms of low estrogen.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableHypoestrogenic symptoms
    Study

    n = 125

    Outcome group
    Adverse events · Reproductive and sexual health

    Source sentences

    Summary
    The main side effects included flare-up effects and hypoestrogenic symptoms.
    2 context sentences
    Summary · context
    A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3.75 mg triptorelin injected intramuscularly or leuprorelin group (62 cases) treated with 3.75 mg leuprorelin injected subcutaneously.
    Summary · context
    Both drugs were injected every 28 days for a total of 3 months.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.